Tehran, Iran – A growing crisis in Iran's pharmaceutical sector has left many citizens unable to access or afford essential and life-saving medicines, with hundreds of products reportedly in short supply nationwide. This situation is unfolding as the United States intensifies its pressure on Iran through military actions, sanctions, and a naval blockade.

For years, Iran has strived for self-sufficiency in medicine production, developing domestic capabilities for active pharmaceutical ingredients, equipment, and finished drugs. However, the sector remains dependent on imports for crucial components and certain medications. The prolonged "maximum pressure" sanctions imposed by Washington have significantly disrupted the financial and logistical channels necessary for these medical imports.

Hadi Ahmadi, a spokesperson for the Iranian Pharmacists Association, stated that approximately 800 pharmaceutical products are currently facing shortages across the country. Of these, 90 are considered essential and life-saving. Alarmingly, 400 of the drugs experiencing shortages are manufactured domestically, indicating a systemic issue beyond reliance on foreign supply chains.

The implications of these shortages are severe, impacting patients with chronic conditions and serious illnesses. Farah, a 59-year-old Tehran resident, has switched from a Swiss-made autoimmune drug to an Iranian equivalent due to cost and availability concerns. She expressed worry about the future availability and efficacy of even the domestic version, highlighting the precariousness of the current situation.

Prices for a wide range of medications have surged dramatically. Reports from the state-run Mehr News Agency indicate that the cost of gabapentin, used for epilepsy and nerve pain, has increased by 220 percent in the past year. Other price hikes include Acetaminophen (pain and fever relief) by 375 percent, Amoxicillin (antibiotic) by 285 percent, and Fluoxetine (anti-depressant) by 100 percent. Insulin, a daily necessity for diabetics, has seen its price increase by as much as sixfold compared to a year ago.

These sharp price increases in the pharmaceutical sector are part of a broader inflationary trend gripping Iran. The country's inflation rate is among the highest globally. In August, the cost of essential food items rose by over 123 percent year-on-year, with staples like cooking oil more than tripling in price.

Despite the mounting evidence of shortages and price hikes, Iranian authorities maintain that the pharmaceutical sector will not collapse. However, the ongoing impact on public health and the daily lives of citizens continues to be a significant concern, raising questions about the long-term sustainability of healthcare access in the country under current conditions.

The current predicament underscores the complex interplay between international geopolitical pressures and domestic healthcare infrastructure, leaving many Iranians bracing for further challenges in accessing essential medical treatments.